(ACLS) Axcelis Technologies - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0545402085
Stock:
Total Rating 63
Risk 69
Buy Signal 0.50
| Risk 5d forecast | |
|---|---|
| Volatility | 62.2% |
| Relative Tail Risk | -7.03% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.04 |
| Alpha | 27.95 |
| Character TTM | |
|---|---|
| Beta | 1.737 |
| Beta Downside | 1.995 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.84% |
| CAGR/Max DD | -0.16 |
EPS (Earnings per Share)
Revenue
Description: ACLS Axcelis Technologies
Axcelis Technologies, Inc. designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips in the United States, Europe, and the Asia Pacific. The company offers high energy, high current, and medium current implanters for various application requirements. It also provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. The company sells its equipment and services to semiconductor chip manufacturers through its direct sales force. Axcelis Technologies, Inc. was founded in 1978 and is headquartered in Beverly, Massachusetts.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 120.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -1.68 > 1.0 |
| NWC/Revenue: 88.86% < 20% (prev 90.00%; Δ -1.15% < -1%) |
| CFO/TA 0.09 > 3% & CFO 118.3m > Net Income 120.2m |
| Net Debt (-103.1m) to EBITDA (159.9m): -0.64 < 3 |
| Current Ratio: 4.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (31.1m) vs 12m ago -4.28% < -2% |
| Gross Margin: 44.91% > 18% (prev 0.45%; Δ 4447 % > 0.5%) |
| Asset Turnover: 61.92% > 50% (prev 75.47%; Δ -13.55% > 0%) |
| Interest Coverage Ratio: 13.17 > 6 (EBITDA TTM 159.9m / Interest Expense TTM 10.8m) |
Altman Z'' 7.12
| A: 0.55 (Total Current Assets 943.2m - Total Current Liabilities 197.7m) / Total Assets 1.36b |
| B: 0.37 (Retained Earnings 503.5m / Total Assets 1.36b) |
| C: 0.11 (EBIT TTM 142.3m / Avg Total Assets 1.36b) |
| D: 1.53 (Book Value of Equity 501.4m / Total Liabilities 326.7m) |
| Altman-Z'' Score: 7.12 = AAA |
Beneish M -2.26
| DSRI: 1.01 (Receivables 168.5m/203.1m, Revenue 839.0m/1.02b) |
| GMI: 0.99 (GM 44.91% / 44.67%) |
| AQI: 2.50 (AQ_t 0.23 / AQ_t-1 0.09) |
| SGI: 0.82 (Revenue 839.0m / 1.02b) |
| TATA: 0.00 (NI 120.2m - CFO 118.3m) / TA 1.36b) |
| Beneish M-Score: -2.26 (Cap -4..+1) = BBB |
What is the price of ACLS shares?
As of March 03, 2026, the stock is trading at USD 86.58 with a total of 682,987 shares traded.
Over the past week, the price has changed by +9.89%, over one month by -2.51%, over three months by +5.03% and over the past year by +57.79%.
Over the past week, the price has changed by +9.89%, over one month by -2.51%, over three months by +5.03% and over the past year by +57.79%.
Is ACLS a buy, sell or hold?
Axcelis Technologies has received a consensus analysts rating of 3.57.
Therefor, it is recommend to hold ACLS.
- StrongBuy: 2
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ACLS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 92 | 6.3% |
| Analysts Target Price | 92 | 6.3% |
ACLS Fundamental Data Overview March 03, 2026
P/E Trailing = 21.7395
P/E Forward = 22.4215
P/S = 3.0521
P/B = 2.4504
P/EG = 1.23
Revenue TTM = 839.0m USD
EBIT TTM = 142.3m USD
EBITDA TTM = 159.9m USD
Long Term Debt = 40.8m USD (from longTermDebtTotal, last quarter)
Short Term Debt = 1.57m USD (from shortTermDebt, last quarter)
Debt = 42.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -103.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.46b USD (2.56b + Debt 42.3m - CCE 145.5m)
Interest Coverage Ratio = 13.17 (Ebit TTM 142.3m / Interest Expense TTM 10.8m)
EV/FCF = 22.97x (Enterprise Value 2.46b / FCF TTM 107.0m)
FCF Yield = 4.35% (FCF TTM 107.0m / Enterprise Value 2.46b)
FCF Margin = 12.75% (FCF TTM 107.0m / Revenue TTM 839.0m)
Net Margin = 14.33% (Net Income TTM 120.2m / Revenue TTM 839.0m)
Gross Margin = 44.91% ((Revenue TTM 839.0m - Cost of Revenue TTM 462.2m) / Revenue TTM)
Gross Margin QoQ = 46.97% (prev 41.57%)
Tobins Q-Ratio = 1.81 (Enterprise Value 2.46b / Total Assets 1.36b)
Interest Expense / Debt = 3.16% (Interest Expense 1.34m / Debt 42.3m)
Taxrate = 14.30% (5.72m / 40.0m)
NOPAT = 122.0m (EBIT 142.3m * (1 - 14.30%))
Current Ratio = 4.77 (Total Current Assets 943.2m / Total Current Liabilities 197.7m)
Debt / Equity = 0.04 (Debt 42.3m / totalStockholderEquity, last quarter 1.03b)
Debt / EBITDA = -0.64 (Net Debt -103.1m / EBITDA 159.9m)
Debt / FCF = -0.96 (Net Debt -103.1m / FCF TTM 107.0m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.87% (Net Income 120.2m / Total Assets 1.36b)
RoE = 11.72% (Net Income TTM 120.2m / Total Stockholder Equity 1.03b)
RoCE = 13.34% (EBIT 142.3m / Capital Employed (Equity 1.03b + L.T.Debt 40.8m))
RoIC = 11.92% (NOPAT 122.0m / Invested Capital 1.02b)
WACC = 12.16% (E(2.56b)/V(2.60b) * Re(12.32%) + D(42.3m)/V(2.60b) * Rd(3.16%) * (1-Tc(0.14)))
Discount Rate = 12.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.93%
[DCF] Terminal Value 61.34% ; FCFF base≈115.7m ; Y1≈100.6m ; Y5≈80.6m
[DCF] Fair Price = 30.12 (EV 822.2m - Net Debt -103.1m = Equity 925.3m / Shares 30.7m; r=12.16% [WACC]; 5y FCF grow -15.89% → 2.90% )
EPS Correlation: -23.76 | EPS CAGR: 5.48% | SUE: 2.81 | # QB: 5
Revenue Correlation: -19.07 | Revenue CAGR: 4.29% | SUE: 4.0 | # QB: 5
EPS next Quarter (2026-06-30): EPS=0.81 | Chg7d=-0.236 | Chg30d=-0.270 | Revisions Net=-4 | Analysts=5
EPS current Year (2026-12-31): EPS=3.64 | Chg7d=-0.750 | Chg30d=-0.850 | Revisions Net=-5 | Growth EPS=-25.4% | Growth Revenue=+0.1%
EPS next Year (2027-12-31): EPS=4.51 | Chg7d=-0.113 | Chg30d=-0.018 | Revisions Net=-1 | Growth EPS=+23.9% | Growth Revenue=+7.7%
[Analyst] Revisions Ratio: -1.00 (0 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.7% (Discount Rate 12.3% - Earnings Yield 4.6%)
[Growth] Growth Spread = -3.2% (Analyst 4.5% - Implied 7.7%)
P/E Forward = 22.4215
P/S = 3.0521
P/B = 2.4504
P/EG = 1.23
Revenue TTM = 839.0m USD
EBIT TTM = 142.3m USD
EBITDA TTM = 159.9m USD
Long Term Debt = 40.8m USD (from longTermDebtTotal, last quarter)
Short Term Debt = 1.57m USD (from shortTermDebt, last quarter)
Debt = 42.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -103.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.46b USD (2.56b + Debt 42.3m - CCE 145.5m)
Interest Coverage Ratio = 13.17 (Ebit TTM 142.3m / Interest Expense TTM 10.8m)
EV/FCF = 22.97x (Enterprise Value 2.46b / FCF TTM 107.0m)
FCF Yield = 4.35% (FCF TTM 107.0m / Enterprise Value 2.46b)
FCF Margin = 12.75% (FCF TTM 107.0m / Revenue TTM 839.0m)
Net Margin = 14.33% (Net Income TTM 120.2m / Revenue TTM 839.0m)
Gross Margin = 44.91% ((Revenue TTM 839.0m - Cost of Revenue TTM 462.2m) / Revenue TTM)
Gross Margin QoQ = 46.97% (prev 41.57%)
Tobins Q-Ratio = 1.81 (Enterprise Value 2.46b / Total Assets 1.36b)
Interest Expense / Debt = 3.16% (Interest Expense 1.34m / Debt 42.3m)
Taxrate = 14.30% (5.72m / 40.0m)
NOPAT = 122.0m (EBIT 142.3m * (1 - 14.30%))
Current Ratio = 4.77 (Total Current Assets 943.2m / Total Current Liabilities 197.7m)
Debt / Equity = 0.04 (Debt 42.3m / totalStockholderEquity, last quarter 1.03b)
Debt / EBITDA = -0.64 (Net Debt -103.1m / EBITDA 159.9m)
Debt / FCF = -0.96 (Net Debt -103.1m / FCF TTM 107.0m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.87% (Net Income 120.2m / Total Assets 1.36b)
RoE = 11.72% (Net Income TTM 120.2m / Total Stockholder Equity 1.03b)
RoCE = 13.34% (EBIT 142.3m / Capital Employed (Equity 1.03b + L.T.Debt 40.8m))
RoIC = 11.92% (NOPAT 122.0m / Invested Capital 1.02b)
WACC = 12.16% (E(2.56b)/V(2.60b) * Re(12.32%) + D(42.3m)/V(2.60b) * Rd(3.16%) * (1-Tc(0.14)))
Discount Rate = 12.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.93%
[DCF] Terminal Value 61.34% ; FCFF base≈115.7m ; Y1≈100.6m ; Y5≈80.6m
[DCF] Fair Price = 30.12 (EV 822.2m - Net Debt -103.1m = Equity 925.3m / Shares 30.7m; r=12.16% [WACC]; 5y FCF grow -15.89% → 2.90% )
EPS Correlation: -23.76 | EPS CAGR: 5.48% | SUE: 2.81 | # QB: 5
Revenue Correlation: -19.07 | Revenue CAGR: 4.29% | SUE: 4.0 | # QB: 5
EPS next Quarter (2026-06-30): EPS=0.81 | Chg7d=-0.236 | Chg30d=-0.270 | Revisions Net=-4 | Analysts=5
EPS current Year (2026-12-31): EPS=3.64 | Chg7d=-0.750 | Chg30d=-0.850 | Revisions Net=-5 | Growth EPS=-25.4% | Growth Revenue=+0.1%
EPS next Year (2027-12-31): EPS=4.51 | Chg7d=-0.113 | Chg30d=-0.018 | Revisions Net=-1 | Growth EPS=+23.9% | Growth Revenue=+7.7%
[Analyst] Revisions Ratio: -1.00 (0 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 7.7% (Discount Rate 12.3% - Earnings Yield 4.6%)
[Growth] Growth Spread = -3.2% (Analyst 4.5% - Implied 7.7%)